BR112017002703A2 - anticorpos específicos de mmp9. - Google Patents

anticorpos específicos de mmp9.

Info

Publication number
BR112017002703A2
BR112017002703A2 BR112017002703-8A BR112017002703A BR112017002703A2 BR 112017002703 A2 BR112017002703 A2 BR 112017002703A2 BR 112017002703 A BR112017002703 A BR 112017002703A BR 112017002703 A2 BR112017002703 A2 BR 112017002703A2
Authority
BR
Brazil
Prior art keywords
mmp9
specific antibodies
fragment
useful
chain variable
Prior art date
Application number
BR112017002703-8A
Other languages
English (en)
Inventor
CHVATCHKO MISSOTTEN Yolande
Goffin Laurence
Leger Olivier
M. DUNN Steven
Power Christine
Maundrell Kinsey
Original Assignee
Calypso Biotech Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calypso Biotech Sa filed Critical Calypso Biotech Sa
Publication of BR112017002703A2 publication Critical patent/BR112017002703A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Abstract

a presente invenção se refere às novas proteínas que se ligam à mmp9 e compreendem pelo menos um fragmento de uma região variável de cadeia pesada e/ou pelo menos um fragmento de uma região variável de cadeia leve de um anticorpo. em particular, as proteínas de ligação à mmp9 de acordo com a invenção são capazes de neutralizar a atividade da mmp9 e são úteis na prevenção e/ou no tratamento das doenças inflamatórias e/ou autoimunes ou cancerígenas. em particular, as proteínas de ligação à mmp9 de acordo com a invenção são úteis no diagnóstico das doenças relacionadas à mmp9.
BR112017002703-8A 2014-08-13 2015-08-13 anticorpos específicos de mmp9. BR112017002703A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14180765.1 2014-08-13
EP14180765.1A EP2985296A1 (en) 2014-08-13 2014-08-13 Antibodies specific for MMP9
PCT/EP2015/068645 WO2016023979A1 (en) 2014-08-13 2015-08-13 Antibodies specific for mmp9

Publications (1)

Publication Number Publication Date
BR112017002703A2 true BR112017002703A2 (pt) 2018-02-27

Family

ID=51301193

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002703-8A BR112017002703A2 (pt) 2014-08-13 2015-08-13 anticorpos específicos de mmp9.

Country Status (13)

Country Link
US (1) US10364296B2 (pt)
EP (2) EP2985296A1 (pt)
JP (1) JP6856523B2 (pt)
KR (1) KR20170041222A (pt)
CN (1) CN106573984A (pt)
AU (1) AU2015303183B2 (pt)
BR (1) BR112017002703A2 (pt)
CA (1) CA2956986A1 (pt)
ES (1) ES2784271T3 (pt)
MX (1) MX2017001959A (pt)
PL (1) PL3180362T3 (pt)
RU (1) RU2714043C2 (pt)
WO (1) WO2016023979A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170306050A1 (en) 2016-04-08 2017-10-26 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2018109222A1 (en) 2016-12-16 2018-06-21 Universite de Bordeaux Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
WO2018220235A1 (en) * 2017-06-02 2018-12-06 Merck Patent Gmbh Mmp13 binding immunoglobulins
US20200124604A1 (en) * 2017-06-30 2020-04-23 National Institutes Of Biomedical Innovation, Health And Nutrition Biomarker for detecting colorectal cancer
JP7109440B2 (ja) * 2017-07-18 2022-07-29 第一三共株式会社 活性型ｍｍｐ－９結合ペプチド
JP2021506763A (ja) * 2017-12-13 2021-02-22 ノース カロライナ ステート ユニバーシティＮｏｒｔｈ Ｃａｒｏｌｉｎａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ 化学療法剤とチェックポイント阻害剤とを含む組成物及び使用の方法
CN108277214B (zh) * 2018-02-23 2021-07-06 广东医科大学 一种应激磷酸化抗原多肽、抗体、制备方法以及应用
WO2020237092A2 (en) * 2019-05-21 2020-11-26 The Regents Of The University Of California Mmp-9 antibodies and methods of use thereof
CN110885375B (zh) * 2019-12-20 2021-07-02 南京融捷康生物科技有限公司 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用
WO2023278491A1 (en) * 2021-06-28 2023-01-05 Releviate, Llc Mmp-9 antibodies and uses thereof
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途
CN117264069B (zh) * 2023-11-23 2024-01-26 再少年(北京)生物科技有限公司 一种促进皮肤组织再生的工程化外泌体的制备方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002235692A1 (en) * 2001-02-23 2002-09-04 Biophage Inc. Methods and compositions for preventing and treating neutrophil-mediated diseases
GB0516069D0 (en) 2005-08-04 2005-09-14 Imp College Innovations Ltd Pharmaceutical and use thereof
KR20090113908A (ko) * 2007-02-23 2009-11-02 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물
US8013125B2 (en) 2008-03-03 2011-09-06 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
US8008445B2 (en) 2008-03-03 2011-08-30 Dyax Corp. Metalloproteinase 9 binding proteins
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
WO2011028883A2 (en) * 2009-09-03 2011-03-10 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
PT2608809T (pt) * 2010-08-27 2019-08-26 Gilead Biologics Inc Anticorpos para a metaloproteinase 9 da matriz
MX2014010449A (es) 2012-02-29 2015-02-10 Gilead Biologics Inc Anticuerpos a metaloproteinasa de matriz 9.
NZ629178A (en) * 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9

Also Published As

Publication number Publication date
EP3180362B1 (en) 2020-02-05
KR20170041222A (ko) 2017-04-14
ES2784271T3 (es) 2020-09-23
JP2017532005A (ja) 2017-11-02
JP6856523B2 (ja) 2021-04-07
PL3180362T3 (pl) 2020-06-15
CN106573984A (zh) 2017-04-19
RU2017107773A3 (pt) 2018-09-13
RU2714043C2 (ru) 2020-02-11
US10364296B2 (en) 2019-07-30
MX2017001959A (es) 2017-05-04
AU2015303183B2 (en) 2021-01-28
EP2985296A1 (en) 2016-02-17
EP3180362A1 (en) 2017-06-21
CA2956986A1 (en) 2016-02-18
RU2017107773A (ru) 2018-09-13
US20170233495A1 (en) 2017-08-17
AU2015303183A1 (en) 2017-02-16
WO2016023979A1 (en) 2016-02-18

Similar Documents

Publication Publication Date Title
BR112017002703A2 (pt) anticorpos específicos de mmp9.
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CL2019003728A1 (es) Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf. (divisional solicitud 201701000)
CO2018004743A2 (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
EA201791485A1 (ru) Анти-cd47-антитела и их применения
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
BR112018074453A2 (pt) proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
BR112018010084A2 (pt) ligantes de pd1 e/ou lag3
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
EA202091540A1 (ru) Антитела к lilrb2
UA117364C2 (uk) Похідні аматоксину
BR112017027549A2 (pt) anticorpo para cd40
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
BR112016030183A2 (pt) anticorpos e fragmentos de ligação ao antígeno que se ligam especificamente à proteína tau associada a microtúbulos
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
EA202091315A2 (ru) Антитела человека, связывающиеся с g-белком rsv
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CALYPSO BIOTECH SA (CH)

B25A Requested transfer of rights approved

Owner name: EA PHARMA CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2735 DE 06-06-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.